Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol®

Biologicals

Volumn 24, Issue 2, 1996, Pages 103-111

  Golker C F ^a   Whiteman, M D ^c   Gugel, K H ^a   Gilles, R ^a   Stadler, Peter ^a   Kovatch, R M ^c   Lister, D ^d   Wisher, M H ^d   Calcagni, C ^b   Hubner G E ^e  

^a BAYER AG   (Germany)

^b BAYER CORPORATION   (United States)

^c Microbiological Associates Inc   (United States)

^d Microbiological Associates Ltd   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ANIMAL TISSUE; ARTICLE; BRAIN SPONGIOSIS; CATTLE; DISEASE MODEL; DRUG MANUFACTURE; DRUG SAFETY; FEMALE; LUNG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCRAPIE AGENT; VIRUS INFECTIVITY;

ANIMALIA; BOS TAURUS; BOVINAE; RODENTIA; SCRAPIE PRION;

EID: 2942741469     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1996.0013     Document Type: Article

References (41)

1. 1. Kraut H, Frey EK, Werle E. Über die Inaktivierung des Kallikrein; Z Physiol Chemie 1930; 192: 1-21.
2. 2. Kassell B, Radicevic M, Berlow S et al. The basic trypsin inhibitor of bovine pancreas. I. An improved method of preparation and amino acid composition. J Biol Chem 1963; 238: 3274-3279.
3. 3. Anderer FA. Strukturuntersuchungen am Kallikrein Inaktivator aus Rinderlunge. II. Bestimmung der Aminosauresequenz. Z f Naturf 1965; 20b: 462-472.
4. 4. Anderer FA, Hornle S. The disulfide linkages in kallikrein inactivator of bovine lung. J Biol Chem 1966; 241: 1568-1572.
5. 5. Deisenhofer J, Steigmann W. Crystallographic refinement of the structure of bovine pancreatic trypsin inhibitor at 1·5 Å resolution. Acta Crystallogr 1975; Sect. B31: 238-250.
6. 6. Berndt KD, Güntert P, Orbons LPM, Wüthrich K. Determination of a high-quality nuclear magnetic resonance solution structure of the bovine pancreatic trypsin inhibitor and comparison with three crystal structures. J Mol Biol 1992; 227: 757-775.
7. 7. Wells GAH, Scott AC, Johnson CT et al. A novel progressive spongiform encephalopathy in cattle. Vet Rec 1987; 121: 419-420.
8. 8. Kimberlin RH. Bovine spongiform encephalopathy. Rev Sci Techn Off Int Epiz 1992; 1: 349-387.
9. 9. Diringer H. Unkonventionelle Viruskrankheiten. Bundesgesundheitsblatt 1990; 5/90: 187-194.
10. 10. Diringer H, Beekes M, Oberdieck U. The nature of the scrapie agent. The virus theory. Ann NY Acad Sci 1994; 724: 246-258.
11. 11. Kimberlin R. Slow viruses: conventional and unconventional. In: Brown F, Wilson G, eds. Principles of bacteriology, virology and immunity. Vol 4 Edward Arnold, 1991: 487-510.
12. 12. Rohwer RG. The scrapie agent: 'a virus by any other name'. In: Chesebro B, ed. Tranmissible spongiform encephalopathies. Curr Top Microbiol Immunol 1991; 172: 195-232.
13. 13. Narang HK. Evidence that homologous ssDNA is present in scrapie, Creutzfeldt-Jakob-Disease, and spongiform encephalopathy. Ann NY Acad Sci 1994; 274: 314-326.
14. 14. Alper T. Scrapie agent unlike viruses in size and susceptibility to inactivation by ionizing or ultraviolet radiation. Nature 1985; 317: 750.
15. 15. Prusiner SB, Bolton DC, Groth DF, Bowmann KA, Cochran SP, McKinley MP. Further purification and characterization of scrapie prions. Biochemistry 1982; 21: 6942-6950.
16. 16. Chesebro B. Spongiform encephalopathies: the transmissible agents. In: Fields BN, Knipe DM et al.., eds. Virology, Second Edition. New York: Raven Press Ltd., 1990; 2325-2336.
17. 17. Prusiner SB, Groth DF, McKinley MP, Cochran SP, Bowman KA, Kasper KC. Thiocyanate and hydroxyl ions inactivate the scrapie agent. Proc Nat, Acad Sci USA 1981; 78: 4606-4610.
18. 18. Taylor DM. Inactivation of BSE agent. Dev Biol Stand 1990; 75: 97-102.
19. 19. Taylor DM. Inactivation of SE agents. Br Med Bull 1993; 49: 810-821.
20. 20. Ernst DR, Race RE. Comparative analysis of scrapie agent inactivation methods. J Virol Methods 1993; 41: 193-202.
21. 21. Taylor MD, Fraser H, McConell I et al. Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol 1994; 139: 313-326.
22. 22. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-144.
23. 23. Prusiner SB, Growth DF, Bolton DC, Kent SB, Hood LE. Purification and structural studies of a major scrapie protein. Cell 1984; 38: 127-134.
24. 24. Prusiner SB. Scrapie prions. Ann Rev Microbiol 1989; 43: 345-374.
25. 25. Prusiner SB. Molecular biology of prion diseases. Science 1991; 252: 1515-1522.
26. 26. Fraser H, Dickinson A. The sequential development of the brain lesions of scrapie in three strains of mice. J Comp Pathol 1968; 78: 301-311.
27. 27. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedeberg's Arch Exp Pathol Pharmakol 1931; 162: 480-483
28. 28. Pocchiari M. Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses. Dev Biol Stand 1990; 75: 87-97.
29. 29. Bolis CL, Gibbs CJ. Proceedings of an international round table on bovine spongiform encephalopathy summary report and recommendations. J Am Vet Assoc 1990; 196: 1673-1690.
30. 30. Danner K. Übertragung spongiformer Encephalopathien durch Arzneimittel. Grundzuge einer Risikobetrachtung. Pharm Ind 1991; 53: 614-623.
31. 31. Sickmüller B. Spongiforme Encephalopathien und Arzneimittel. Sachstand und Grundzuge einer Risikobetrachtung. Pharm Ind 1991; 53: 613-614.
32. 32. Kimberlin RH. Bovine spongiform encephalopathy (BSE): myths and reality. Biomed Prog 1991; 4: 39-42.
33. 33. Bekanntmachungen der Empfehlungen zur Minderung des Infektionsrisikos durch Zoonosenerreger und sonstige Erreger von Tierinfektionen bei der Herstellung von Arzneimitteln (Zoonosen-Empfeh-lungen). German Federal Journal for Official Publications (Bundesanzeiger) Nr. 164, 15. August 1991; 6120 ff.
34. 34. Meeting Report. Bovine spongiform encephalopathy and related agents: risk factors of biological products. An informal consultation/working meeting (held on November 6-7. 1990, Annecy, France). Toxicol Pathol 1991; 19: 293-297.
35. 35. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines. EEC Regulatory Document - Validation of Virus Removal and Inactivation Procedures. Biologicals 1991; 19: 247-251.
36. 36. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines. EEC Regulatory Document - Guidelines for Minimizing the Risk of Transmission of Agents Causing Spongiform Encephalopathies via Medicinal Products. Biologicals 1992; 20: 155-158 (Document No. III 3298/91).
37. 37. Report of a WHO consultation of public health issues related to animal and human spongiform encephalopathies. Geneva, 12-14 November 1991. World Health Organization EHO/CDS/VPH/92. 104.
38. 38. Bekanntmachung der Sicherheitsanforderungen an Arzneimittel aus Korperbestandteilen von Rind Schaf oder Ziege zur Vermeidung des Risikos einerr Übertragung von BSE bzw. Scrapie. German Federal Journal for Official Publications (Bundesanzeiger), 26 February 1994; 1851 ff.
39. 39. Spongiform Encephalopathy Advisory Committee. Transmissible Spongiform Encephalopathies, a Summary of Present Knowledge and Research. Her Majesty's Stationery Office 1994; 66.
40. 40. Gibbs CJ, Jr, Gajdusek DC, Morris JA. Viral characteristics of the scrapie agent in mice. In: Gajdusek DC, Gibbs CJ, Jr, Alpers M, eds. Slow, Latent and Temperate Virus Infections, NINDB2 Monograph No 2, Washington, US Government Printing Office, 1965: 195-202.
41. 41. Safar J, Wang W, Padgett MP et al. Molecular mass, biochemical composition, and physicochemical behaviour of the infectious form of the scrapie precursor protein monomer. Proc Natl Acad Sci USA 1990; 87: 6373-6377.